PubMed COVID-19 Clinical Care

Molnupiravir (MOV) is an oral antiviral for the treatment of COVID-19 in outpatient settings. This analysis investigated the relationship between β-D-N4-hydroxycytidine (NHC) pharmacokinetics (PK) and clinical outcomes in patients with mild to

CONCLUSION: Our study is one of the rare studies examining the relationship between (COVID- 19) and 25(OH)-D vitamins in the pediatric age group. Children with (COVID-19) have a lower 25(OH)-D vitamin level than the control group.

Background The nationwide lockdown was imposed upon by the Government of Nepal with regards to the COVID-19 pandemic. Even during times of limited mobility and travel, trauma cases were presenting to the hospital. Objective To asses trauma patterns

No abstract

CONCLUSIONS: The study suggests that interventions should focus on promoting healthy dietary patterns among young adults who frequently use MFDAs. Teaching cooking skills, especially among young males, and time management skills could be useful to

CONCLUSION: We revealed important S protein-specific differential biomarkers in individuals affected by COVID-19, bringing new insights into the inflammatory status or SARS-CoV-2 exposition determination.

CONCLUSIONS: Clinical and anthropological research provides strong grounds for investing in clinical leadership. The stability of 'prestige-based' leadership can be contrasted with the outcomes of 'dominance-based' leadership that relies on force

CONCLUSIONS: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.

CONCLUSIONS: We showed that ongoing symptoms were frequently reported by English schoolchildren regardless of SARS-CoV-2 test results and some specific symptoms such as loss of smell and taste were more prevalent in those with a positive test history

The worldwide inequitable access to vaccination claims for a re-assessment of policies that could minimize the COVID-19 burden in low-income countries. Nine months after the launch of the national vaccination program in March 2021, only 3.4% of the